iBio, Inc. cotiza a 0.90 USD y tiene una capitalización bursátil de $45M. En los últimos 12 meses ha facturado $100000 con un margen de flujo de caja libre del -23796.0%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting anti…
| Periodo | 2026-08 | 2026-02 | 2025-11 | 2025-09 |
|---|---|---|---|---|
| Real | $-0.07 | $-0.09 | $-0.11 | $-0.32 |
| Estimado | $-0.06 | $-0.06 | $-0.07 | $-0.36 |
| Sorpresa | -16.7% | -50.0% | -57.1% | +11.1% |
| Métrica | IBIO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -35141.0% | -38.6% | -35102.4% |
| Net Margin | -33044.0% | -33.6% | -33010.4% |
| FCF Margin | -23796.0% | -13.9% | -23782.1% |
| ROE | -38.5% | -40.4% | +1.9% |
| ROA | -33.3% | -32.0% | -1.3% |
| Current Ratio | 7.85 | 2.84 | +5.01 |
| Debt / Equity | — | 0.28 | — |